Dalbavancin in clinical practice in Spain: a 2 year retrospective study

OBJECTIVES: Dalbavancin is approved for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) in adults. Its unique pharmacokinetic properties allow daily dosing to be avoided. The objective was to describe the sociodemographic and clinical characteristics of patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Morata, Laura, Aguado, José María, Salavert, Miguel, Pasquau, Juan, Míguez, Enrique, Muñoz, Patricia, Rosselló, Irantzu, Almirante, Benito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777743/
https://www.ncbi.nlm.nih.gov/pubmed/36570687
http://dx.doi.org/10.1093/jacamr/dlac120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777743/
https://www.ncbi.nlm.nih.gov/pubmed/36570687
http://dx.doi.org/10.1093/jacamr/dlac120

Ejemplares similares